Ironwood Pharmaceuticals IRWD Stock
Ironwood Pharmaceuticals Price Chart
Ironwood Pharmaceuticals IRWD Financial and Trading Overview
| Ironwood Pharmaceuticals stock price | 7.88 USD |
| Previous Close | 11.05 USD |
| Open | 11.05 USD |
| Bid | 0 USD x 1800 |
| Ask | 0 USD x 2900 |
| Day's Range | 10.95 - 11.13 USD |
| 52 Week Range | 9.73 - 12.66 USD |
| Volume | 1.51M USD |
| Avg. Volume | 2.43M USD |
| Market Cap | 1.71B USD |
| Beta (5Y Monthly) | 0.920774 |
| PE Ratio (TTM) | 11.03 |
| EPS (TTM) | -6.45 USD |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 14.33 USD |
IRWD Valuation Measures
| Enterprise Value | 1.39B USD |
| Trailing P/E | 11.03 |
| Forward P/E | 12.120878 |
| PEG Ratio (5 yr expected) | 0.16 |
| Price/Sales (ttm) | 4.1077714 |
| Price/Book (mrq) | 2.4241757 |
| Enterprise Value/Revenue | 3.337 |
| Enterprise Value/EBITDA | 5.482 |
Trading Information
Ironwood Pharmaceuticals Stock Price History
| Beta (5Y Monthly) | 0.920774 |
| 52-Week Change | -3.41% |
| S&P500 52-Week Change | 20.43% |
| 52 Week High | 12.66 USD |
| 52 Week Low | 9.73 USD |
| 50-Day Moving Average | 10.75 USD |
| 200-Day Moving Average | 11.07 USD |
IRWD Share Statistics
| Avg. Volume (3 month) | 2.43M USD |
| Avg. Daily Volume (10-Days) | 1.94M USD |
| Shares Outstanding | 155.35M |
| Float | 136.53M |
| Short Ratio | 7.6 |
| % Held by Insiders | 1.81% |
| % Held by Institutions | 112.76% |
| Shares Short | 17.62M |
| Short % of Float | 18.55% |
| Short % of Shares Outstanding | 11.34% |
Dividends & Splits
| Trailing Annual Dividend Rate | 0 |
| Trailing Annual Dividend Yield | 0% |
| 5 Year Average Dividend Yield | N/A |
| Payout Ratio | 0 |
| Last Split Factor | 1194:1000 |
Financial Highlights
Fiscal Year
| Fiscal Year Ends | December 31, 2022 |
| Most Recent Quarter (mrq) | March 31, 2023 |
| Next Fiscal Year End | December 31, 2023 |
Profitability
| Profit Margin | 43.62% |
| Operating Margin (ttm) | 60.55% |
| Gross Margin | 88.90% |
| EBITDA Margin | 60.87% |
Management Effectiveness
| Return on Assets (ttm) | 14.10% |
| Return on Equity (ttm) | 29.72% |
Income Statement
| Revenue (ttm) | 417.13M USD |
| Revenue Per Share (ttm) | 2.72 USD |
| Quarterly Revenue Growth (yoy) | 6.70% |
| Gross Profit (ttm) | 366.33M USD |
| EBITDA | 253.94M USD |
| Net Income Avi to Common (ttm) | 181.98M USD |
| Diluted EPS (ttm) | 1 |
| Quarterly Earnings Growth (yoy) | 17.80% |
Balance Sheet
| Total Cash (mrq) | 740.34M USD |
| Total Cash Per Share (mrq) | 4.77 USD |
| Total Debt (mrq) | 415.84M USD |
| Total Debt/Equity (mrq) | 58.83 USD |
| Current Ratio (mrq) | 36.337 |
| Book Value Per Share (mrq) | 4.55 |
Cash Flow Statement
| Operating Cash Flow (ttm) | 289.81M USD |
| Levered Free Cash Flow (ttm) | 170.66M USD |
Profile of Ironwood Pharmaceuticals
| Country | United States |
| State | MA |
| City | Boston |
| Address | 100 Summer Street |
| ZIP | 02110 |
| Phone | 617 621 7722 |
| Website | https://www.ironwoodpharma.com |
| Industry | Drug Manufacturers-Specialty & Generic |
| Sector(s) | Healthcare |
| Full Time Employees | 219 |
Ironwood Pharmaceuticals, Inc., a healthcare company, focuses on the development and commercialization of gastrointestinal (GI) products. It markets linaclotide, a guanylate cyclase type-C (GC-C) agonist for the treatment of adults suffering from irritable bowel syndrome with constipation or chronic idiopathic constipation under the LINZESS name in the United States, Mexico, Japan, and China, as well as under the CONSTELLA name in the Canada and European countries. The company is also developing IW-3300, a GC-C agonist for the treatment of visceral pain conditions, including interstitial cystitis/bladder pain syndrome and endometriosis; and CNP-104, an immune nanoparticle for the treatment of primary biliary cholangitis. The company has strategic partnerships with AbbVie Inc., AstraZeneca AB, and Astellas Pharma Inc. for the development and commercialization of linaclotide. The company was formerly known as Microbia, Inc. and changed its name to Ironwood Pharmaceuticals, Inc. in April 2008. Ironwood Pharmaceuticals, Inc. was incorporated in 1998 and is headquartered in Boston, Massachusetts.
Q&A For Ironwood Pharmaceuticals Stock
What is a current IRWD stock price?
Ironwood Pharmaceuticals IRWD stock price today per share is 7.88 USD.
How to purchase Ironwood Pharmaceuticals stock?
You can buy IRWD shares on the NasdaqGS exchange. Contact your financial advisor to select a broker.
What is the ticker symbol for Ironwood Pharmaceuticals?
The stock symbol or ticker of Ironwood Pharmaceuticals is IRWD.
Which industry does the Ironwood Pharmaceuticals company belong to?
The Ironwood Pharmaceuticals industry is Drug Manufacturers-Specialty & Generic.
How many shares does Ironwood Pharmaceuticals have in circulation?
The max supply of Ironwood Pharmaceuticals shares is 156.53M.
What is Ironwood Pharmaceuticals Price to Earnings Ratio (PE Ratio)?
Ironwood Pharmaceuticals PE Ratio is now.
What was Ironwood Pharmaceuticals earnings per share over the trailing 12 months (TTM)?
Ironwood Pharmaceuticals EPS is -6.45 USD over the trailing 12 months.
Which sector does the Ironwood Pharmaceuticals company belong to?
The Ironwood Pharmaceuticals sector is Healthcare.
Ironwood Pharmaceuticals IRWD included in indexes
| Name Name | Price Price |
24h% 7d chart 24h% & 7d |
VOL Volume | 24h low | 24h high | Volume |
|---|
| Name Name | Price Price |
24h% 7d chart 24h% & 7d |
VOL Volume | 24h low | 24h high | Volume | |
|---|---|---|---|---|---|---|---|
| {{ item.name }} {{ item.symbol }} | {{ item.price }} {{ item.price_usd }} |
{{ item.change_pct }}
|
{{ item.volume }} {{ item.volume_usd }} | {{ item.low }} {{ item.low_usd }} | {{ item.high }} {{ item.high_usd }} | {{ item.components_count }} - | {{ item.volume }} {{ item.volume_usd }} |
| NASDAQ Composite IXIC | 16175.09 USD — |
-1.62
|
3.94B USD — | 16125.33 USD — | 16341.46 USD — | — - | 3.94B USD — |
| NASDAQ Biotechnology NBI | 4195.13 USD — |
-2.14
|
— — | 4174.1 USD — | 4266.29 USD — | — - | — — |
| NASDAQ HealthCare IXHC | 958.68 USD — |
-2.07
|
— — | 954.08 USD — | 972.42 USD — | — - | — — |
| NASDAQ Global Buyback Achievers DRBG | 2057.38 USD — |
-0.89
|
— — | 2057.25 USD — | 2057.65 USD — | — - | — — |
| NASDAQ Composite Total Return I XCMP | 19659.36 USD — |
-1.62
|
— — | 19598.88 USD — | 19861.56 USD — | — - | — — |
| Nasdaq US 700 Small Cap Value I NQUS700SCV | 2024.5 USD — |
-1.58
|
— — | 2018.28 USD — | 2050.17 USD — | — - | — — |
| Nasdaq US Smart Pharmaceuticals NQSSPH | 1383.38 USD — |
-2.07
|
— — | 1380.57 USD — | 1408.57 USD — | — - | — — |
| Stlmt ID NASDAQ Biotechnology NBX | 4604.4 USD — |
-2.98
|
— — | 4555.41 USD — | 4917.8 USD — | — - | — — |
| NASDAQ US Buyback Achievers Sel DRBS | 2224.13 USD — |
-1.64
|
— — | 2217.6 USD — | 2253.41 USD — | — - | — — |
| NASDAQ Biotechnology Total Retu XNBI | 4501.69 USD — |
-2.14
|
— — | 4479.13 USD — | 4578.05 USD — | — - | — — |
| Nasdaq US 700 Small Cap Value N NQUS700SCVN | 2248.88 USD — |
-1.58
|
— — | 2241.98 USD — | 2277.4 USD — | — - | — — |
| Nasdaq US 700 Small Cap Index NQUS700SC | 2060.1 USD — |
-1.99
|
— — | 2051.95 USD — | 2093.4 USD — | — - | — — |
| NASDAQ Global Select Market Com NQGS | 7876.03 USD — |
-1.61
|
— — | 7852.08 USD — | 7955.84 USD — | — - | — — |
- {{ link.label }} {{link}}